drugset / Trial / NCT04102241
Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis.After single asending dose and mutiple asending dose in health subjects. And the patients with moderate to severe plaque psoriasis will be randomized into 4 cohorts(15mg, 30mg, 60mg and placebo) approximately 216 subjects will be enrolled (52 for each cohort ). This study includes an 16-week treatment Period, then a 36-week Treatment Period without placebo.
Timeline
- Start
- 2019-05-30
- Primary completion
- 2020-10-12
- Completion
- 2021-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MUFEMILAST | Small molecule | 15 mg | — |
| Subject | MUFEMILAST | Small molecule | 30 mg | — |
| Subject | MUFEMILAST | Small molecule | 60 mg | — |